文献速递青光眼

英国生物银行中的青光眼:基于诊断与基于治疗定义的比较

Glaucoma in the UK Biobank: A Comparison of Diagnostic-Based versus Treatment-Based Definitions.
PubMed 文献 · Ophthalmology · 2026-06-17

结果显示,同时结合诊断与治疗证据的定义比仅基于诊断的定义产生显著更强的比值比,提示这对人群生物银行中的青光眼研究具有重要意义。

要点

  • 结合诊断与治疗证据的青光眼定义与IOPcc、mRNFL、mGCL的关联强度显著高于仅诊断定义。
  • 最高5% IOPcc在诊断+治疗组的OR为23.6,仅诊断组为11.4(差异P<1×10-10)。
  • 最薄5% mRNFL在诊断+治疗组OR为8.0,仅诊断组为4.7(差异P=2.32×10-7)。

核心结论

  • 同时结合诊断和治疗证据的青光眼定义与IOPcc、mRNFL和mGCL的比值比显著强于仅基于诊断证据的定义。

研究设计与样本

  • 比较已确立危险因素和严重程度生物标志物与不同青光眼定义之间的比值比。

主要发现

  • 最高5% IOPcc的OR在诊断+治疗组为23.6(95%CI 21.3-26.2),仅诊断组为11.4(95%CI 10.6-12.3),差异P<1×10-10。
  • 最薄5% mRNFL的OR在诊断+治疗组为8.0(95%CI 6.9-9.2),仅诊断组为4.7(95%CI 4.2-5.3),差异P=2.32×10-7。
  • 最薄5% mGCL的OR在诊断+治疗组为7.1(95%CI 6.1-8.3),仅诊断组为4.2(95%CI 3.7-4.7),差异P=2.53×10-7。
  • 最高5% PRS的OR在诊断+治疗组为8.4(95%CI 7.9-8.8),仅诊断组为5.6(95%CI 5.4-5.9),差异P<1×10-10。
  • 其他研究的风险因素也呈现相似模式。

关键数值与推荐

  • 诊断+治疗组定义:诊断加上使用青光眼特异性药物或手术治疗的证据(n=7012),在基线或随访期间。

临床怎么用

  • 在人群生物银行青光眼研究中,采用结合诊断与治疗证据的定义可能提高与危险因素和严重程度生物标志物关联的强度。
  • 临床解读生物银行研究结果时需注意青光眼定义方式对关联估计的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare, in the context of a population-scale biobank, associations of established risk factors and severity biomarkers with different glaucoma disease definitions. DESIGN: Observational cohort study. PARTICIPANTS: Five hundred three thousand three hundred twenty-five participants in the UK Biobank. METHODS: Odds ratios (ORs) for associations of established risk factors (corneal-compensated intraocular pressure [IOPcc] and polygenic risk score [PRS]) and clinical biomarkers of disease severity (macular retinal nerve fiber layer [mRNFL] and macular ganglion cell layer [mGCL] thickness) with different glaucoma definitions. MAIN OUTCOME MEASURES: Participants without glaucoma (n = 481 772) were compared with those with: (1) a diagnosis of glaucoma based on self-report or hospital inpatient or primary care records (diagnosis-only group; n = 16 154); or (2) a diagnosis plus evidence of treatment with glaucoma-specific medication or surgery (diagnosis and treatment group; n = 7012), either at baseline or during follow-up. RESULTS: For participants in the highest 5% of IOPcc compared with the remainder, ORs were 23.6 (95% confidence interval [CI], 21.3-26.2) in the diagnosis and treatment group versus 11.4 (95% CI, 10.6-12.3; P < 1 × 10-10 for difference) in the diagnosis-only group. Corresponding ORs were: 8.0 (95% CI, 6.9-9.2) in the diagnosis and treatment group vs 4.7 (95% CI, 4.2-5.3; P = 2.32 × 10-7 for difference) in the diagnosis-only group for the thinnest 5% mRNFL; 7.1 (95% CI, 6.1-8.3) in the diagnosis and treatment group vs 4.2 (95% CI, 3.7-4.7; P = 2.53 × 10-7 for difference) in diagnosis-only group for the thinnest 5% mGCL; and 8.4 (95% CI, 7.9-8.8) in the diagnosis and treatment group versus 5.6 (95% CI, 5.4-5.9; P < 1 × 10-10 for difference) in the diagnosis-only group for the highest 5% PRS. Similar patterns were found for the other risk factors studied. CONCLUSIONS: Definitions of glaucoma that combine both diagnostic and treatment evidence yielded substantially stronger ORs with IOPcc, mRNFL, and mGCL than definitions based on diagnostic evidence alone, suggesting implications for studies of glaucoma in population biobanks. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Schierding W, Khoo A, Akeroyd E, et al. Glaucoma in the UK Biobank: A Comparison of Diagnostic-Based versus Treatment-Based Definitions. Ophthalmology. 2026. PMID: 42309491. doi:10.1016/j.ophtha.2026.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。